{
    "clinical_study": {
        "@rank": "162985", 
        "arm_group": [
            {
                "arm_group_label": "Subjects receiving XIENCE Prime - Long Length (LL)", 
                "description": "300 patients receive LL stent in 28, 33, or 38 mm length"
            }, 
            {
                "arm_group_label": "Subjects receiving XIENCE Prime - Core Length", 
                "description": "200 patients receive Core Length stent in 8, 12, 15, 18 or 23 mm length"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of the PMS are to observe the frequency, type, and degree of device\n      deficiency to assure the safety of the new medical device (XIENCE Prime) as well as to\n      collect information on evaluation of the efficacy and safety for reevaluation."
        }, 
        "brief_title": "XIENCE PRIME Everolimus Eluting Coronary Stent Post Marketing Surveillance (PMS) in Japan", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Angina", 
            "Chronic Coronary Occlusion", 
            "Coronary Artery Disease", 
            "Coronary Artery Stenosis", 
            "Myocardial Ischemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Ischemia", 
                "Coronary Occlusion", 
                "Coronary Stenosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with ischemic heart disease who are eligible for treatment with XIENCE PRIME\n             Everolimus Eluting Stent\n\n          -  Patient provides Informed Consent Form\n\n        Exclusion Criteria:\n\n          -  If it is known at the time of index procedure that the patient is not able to return\n             for the 8-month follow-up visit for angiogram and for the 1-year clinical follow-up,\n             then the patient should not be registered in the PMS."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Only patients in Japan, who are eligible to receive treatment for coronary arteries using\n        the XIENCE PRIME Everolimus-Eluting Stent System are to be enrolled."
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721096", 
            "org_study_id": "12-398"
        }, 
        "intervention": [
            {
                "arm_group_label": "Subjects receiving XIENCE Prime - Long Length (LL)", 
                "description": "Long Length", 
                "intervention_name": "Subjects receiving XIENCE Prime - Long Length (LL)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Subjects receiving XIENCE Prime - Core Length", 
                "description": "Core Length", 
                "intervention_name": "Subjects receiving XIENCE Prime - Core Length", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Angioplasty", 
            "Drug eluting stents", 
            "Stents", 
            "Real world"
        ], 
        "lastchanged_date": "July 15, 2013", 
        "location": {
            "contact": {
                "last_name": "Isao Tsuchii, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "108-6304"
                }, 
                "name": "Abbott Vascular Japan Co., Ltd."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "2", 
        "official_title": "XIENCE PRIME JAPAN PMS", 
        "overall_contact": {
            "email": "isao.tsuchii@av.abbott.com", 
            "last_name": "Isao Tsuchii", 
            "phone": "81-3-4560-0980"
        }, 
        "overall_official": {
            "affiliation": "Teikyo University Hospital, Toyko", 
            "last_name": "Ken Kozuma, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.", 
                "measure": "Stent thrombosis (ST)", 
                "safety_issue": "Yes", 
                "time_frame": "8 months post index procedure"
            }, 
            {
                "description": "Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.", 
                "measure": "Stent thrombosis (ST)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year post index procedure"
            }, 
            {
                "description": "Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.", 
                "measure": "Stent thrombosis (ST)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years post index procedure"
            }, 
            {
                "description": "Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.", 
                "measure": "Stent thrombosis (ST)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years post index procedrue"
            }, 
            {
                "description": "Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.", 
                "measure": "Stent thrombosis (ST)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years post index procedure"
            }, 
            {
                "description": "Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition.", 
                "measure": "Stent thrombosis (ST)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years post index procedure"
            }, 
            {
                "description": "AE caused by Antiplatelet medications include but not limited to\nHepatic disorder\nGranulocytopenia\nThrombotic Thrombocytopenic Purpura", 
                "measure": "Adverse events (AE) caused by Anti-platelet Medications", 
                "safety_issue": "Yes", 
                "time_frame": "8 months post index procedure"
            }, 
            {
                "description": "AE caused by Antiplatelet medications include but not limited to\nHepatic disorder\nGranulocytopenia\nThrombotic Thrombocytopenic Purpura", 
                "measure": "Adverse events (AE) caused by Anti-platelet Medications", 
                "safety_issue": "Yes", 
                "time_frame": "1 year post index procedure"
            }, 
            {
                "description": "AE caused by Antiplatelet medications include but not limited to\nHepatic disorder\nGranulocytopenia\nThrombotic Thrombocytopenic Purpura", 
                "measure": "Adverse events (AE) caused by Anti-platelet Medications", 
                "safety_issue": "Yes", 
                "time_frame": "2 years post index procedure"
            }, 
            {
                "description": "AE caused by Antiplatelet medications include but not limited to\nHepatic disorder\nGranulocytopenia\nThrombotic Thrombocytopenic Purpura", 
                "measure": "Adverse events (AE) caused by Anti-platelet Medications", 
                "safety_issue": "Yes", 
                "time_frame": "3 years post index procedure"
            }, 
            {
                "description": "AE caused by Antiplatelet medications include but not limited to\nHepatic disorder\nGranulocytopenia\nThrombotic Thrombocytopenic Purpura", 
                "measure": "Adverse events (AE) caused by Anti-platelet Medications", 
                "safety_issue": "Yes", 
                "time_frame": "4 years post index procedure"
            }, 
            {
                "description": "AE caused by Antiplatelet medications include but not limited to\nHepatic disorder\nGranulocytopenia\nThrombotic Thrombocytopenic Purpura", 
                "measure": "Adverse events (AE) caused by Anti-platelet Medications", 
                "safety_issue": "Yes", 
                "time_frame": "5 years post index procedure"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abbott Vascular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Vascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}